Recent Updates
Recently added Catalysts
CLLS Positive Sentiment Score: 70/100

Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on

Tuesday, June 27, 2023 2 min read
Key Takeaway: Cellectis S.A. held its annual general meeting on June 27, 2023, in Paris, where resolutions 1 through 28 were adopted while resolution 29 was rejected. The meeting saw more than 72% of shares exercised, reflecting significant participation from shareholders. The company, a clinical-stage biotechnology firm, is recognized for its innovative gene-editing platform aimed at developing therapies for various diseases. Cellectis focuses on CAR-T immunotherapies and has been active in the field for over 23 years.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cellectis adopted resolutions 1 through 28 at the shareholders meeting.
  • Over 72% of shares were exercised, indicating strong shareholder engagement.
  • Cellectis continues to be at the forefront of gene-editing technology.

Full Press Release Details

Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 27, 2023
June 28, 2023 New York (N.Y.) Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company
using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt,
4th floor, 75013 Paris, France.
At the meeting, during which more than 72% of shares were exercised,
Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations.
The detailed results of the vote and
the resolutions are available on the company s website: https://www.cellectis.com/en/investors/general-meetings/
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis
utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem
cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN , its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis
headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For more information, visit our website www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube
For further information on Cellectis, please contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Frequently Asked Questions

When did Cellectis hold its annual general meeting?

Cellectis held its annual general meeting on June 27, 2023.

Where was the Cellectis meeting held?

The meeting took place at the Biopark auditorium in Paris, France.

Which resolutions were adopted during the meeting?

Resolutions 1 through 28 were adopted, while resolution 29 was rejected.

What technology does Cellectis use for gene editing?

Cellectis utilizes TALEN technology for gene editing.

How can I find more information about Cellectis?

More information is available on Cellectis' website at www.cellectis.com.

Tags: CLLS Viatris Investor Conferences Healthcare Cellectis gene editing CAR-T therapies biotechnology clinical-stage
Last updated: Jun 27, 2023